Best printers for Home

Best Mixer Grinder

Best wired Earphones

Best 43 Inch TV in India

Best Wi Fi Routers

Best Home Theatre in India

Smart Watch under 5000

Best Laptops for Education

Best Laptop for Students

New Delhi, Hyderabad-based <keyword id="149108" type="PERSON" weightage="20" keywordseo="Bharat-Biotech">Bharat Biotech</keyword> will make a presentation before the <keyword id="3923779" type="COMPANY" weightage="20" keywordseo="subject-expert-committee">Subject Expert Committee</keyword> of the Central Drug Standard Control Organisation (CDSCO) on Wednesday evening for approval of its <keyword id="24209" type="PERSON" weightage="20" keywordseo="vaccine">vaccine</keyword> - Covaxin, government sources. Earlier on Wednesday, the <keyword id="95879" type="COMPANY" weightage="20" keywordseo="Serum-Institute-of-India">Serum Institute of India</keyword> (SII)'s application for emergency use authorisation of its Covid-19 vaccine was also considered by the Subject Expert Committee. The development came hours after the United Kingdom accepted the recommendation of the Medicines and Healthcare Regulatory Agency (MHRA) to authorise the Oxford University-AstraZeneca's Covid-19 vaccine, <keyword id="9617748" type="COMPANY" weightage="20" keywordseo="covishield">Covishield</keyword>, for emergency approval use. The authorisation was significant for India as the Pune-based Serum Institute of India had tied up with Oxford University-AstraZeneca to manufacture the vaccine in India. America's Pfizer was the first to apply on December 4, followed by Serum Institute of India and Bharat Biotech, who applied on December 6 and 7, respectively. Pfizer has, however, requested more time to make its presentation before the committee. On December 9, the Subject Expert Committee had, however, asked Serum Institute of India and Bharat Biotech to submit more data and information to get emergency use approval (EUA) for their vaccine candidates. The expert panel had then asked SII to submit the outcome of the assessment of UK-MHRA for grant of emergency use approval, the updated safety data of the Phase-II/III clinical trials and immunogenecity data from the clinical trial in the UK and India. Bharat Biotech was recommended to present the safety and efficacy data from the ongoing Phase-III clinical trial in the country for further consideration. Both the firms had again submitted their applications last week seeking approval of the vaccine. The Central government plans to vaccinate nearly 30 crore <keyword id="6360040" type="UNKNOWN" weightage="20" keywordseo="people">people</keyword> in the first phase of the vaccine drive. It would be offered to one crore healthcare workers, along with two crore frontline and essential workers and 27 crore elderly people, mostly above 50 years with comorbidities. SEE ALSO: <a href="https://www.businessinsider.in/stock-market/news/top-stocks-to-watch-sbi-hdfc-bank-wipro-ril-future-retail-tcs-jindal-stainless-upl-irctc-and-others/articleshow/80019871.cms">Top stocks to watch — SBI, HDFC Bank, Wipro, RIL, Future Retail, TCS, Jindal Stainless, UPL, IRCTC, and others</a> <a href="https://www.businessinsider.in/india/news/india-detects-14-new-cases-of-uk-covid-19-strain-putting-the-tally-at-20/articleshow/80020163.cms">India detects 14 new cases of UK COVID-19 strain, putting the tally at 20India detects 14 new cases of UK COVID-19 strain, putting the tally at 20</a> <a href="https://www.businessinsider.in/business/startups/news/2021-could-finally-be-the-year-of-indias-tech-ipos-as-startups-like-zomato-delhivery-policybazaar-head-for-the-public-markets/slidelist/80019978.cms">2021 could finally be the year of India’s tech IPOs as startups like Zomato, Delhivery, Policybazaar head for the public markets</a>

After SII's Covishield, Bharat Biotech plans to put its COVID-19 vaccine for approval before expert panel

The <keyword id="54656" type="General" weightage="20" keywordseo="indian-embassy" source="Orion">Indian Embassy</keyword> in Rome said on Friday that the country has recognised the <keyword id="9617748" type="General" weightage="100" keywordseo="covishield" source="Orion">Covishield</keyword> vaccine and people who have received the jab are now eligible for a <keyword id="9276440" type="General" weightage="80" keywordseo="green-pass" source="Orion">Green Pass</keyword>. With <keyword id="21474" type="General" weightage="80" keywordseo="italy" source="Orion">Italy</keyword>'s recognition, a total 19 European Union (EU) nations have given their go-ahead to Covishield. This is the outcome of a G20 Health Ministers meeting between Union Health Minister <keyword id="2607815" type="General" weightage="20" keywordseo="mansukh-mandaviya" source="Orion">Mansukh Mandaviya</keyword> and his Italian counterpart Roberto Speranza, the Embassy said in a tweet. "Indian vaccine CardHolders are now eligible for the Green Pass," it added Prior to this, Italy had recognised Comirnaty - Pfizer, Moderna, Vaxzervria - AstraZeneca, and <keyword id="92247" type="General" weightage="20" keywordseo="johnson-johnson" source="Orion">Johnson &amp; Johnson</keyword> vaccines as valid. The other 18 EU nations that have recognised the Covishield vaccine are Austria, Belgium, Bulgaria, Croatia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Latvia, Netherlands, Romania, Slovenia, Spain, Sweden, and Switzerland. Meanwhile, the vaccine row with the UK continues as it has recognised the jab but a 10-day quarantine has been made mandatory which will come into the effect from October 4. Terming the present UK travel restrictions as discrimatory, Union Health Secretary Rajesh Bhushan said that "we have the right to reciprocate in the same manner". However, the British High Commissioner to India Alex Ellis said that Covishield vaccine is not a problem and the UK is open to travel. "We're clear Covishield is not a problem. The UK is open to travel and we're already seeing a lot of people going from India to the UK, be it tourists, business people or students". SEE ALSO: <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/science/environment/news/heres-how-researchers-are-considering-fly-ash-recycled-phones-and-slag-to-lower-global-carbon-emissions-from-cement/articleshow/86477965.cms">Here’s how researchers are considering fly ash, recycled phones and slag to lower global carbon emissions from cement</a> <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/india/news/bharat-bandh-called-by-dmk-on-september-27-to-protect-the-rights-of-the-farming-community/articleshow/86474697.cms">Bharat Bandh called by DMK on September 27 to 'protect the rights of the farming community'</a>

After UK and US, Italy also gives green pass to Covishield vaccine

<keyword id="242973" type="General" weightage="20" keywordseo="serum-institute" source="Orion">Serum Institute</keyword> of India (SII) plans to launch a COVID vaccine for children in the next six months, the company's CEO <keyword id="383467" type="General" weightage="20" keywordseo="adar-poonawalla" source="Orion">Adar Poonawalla</keyword> said on Tuesday. Participating in an industry conference, Poonawalla said the vaccine '<keyword id="10678894" type="General" weightage="20" keywordseo="covovax" source="Orion">Covovax</keyword>' is under trial and would offer protection to children all the way down till three years. Currently, <keyword id="9617748" type="General" weightage="20" keywordseo="covishield" source="Orion">Covishield</keyword> and other COVID vaccines are approved for people above the age of 18 years. "We haven't seen a lot of severe disease in children. Fortunately, the panic is not there for children. However, we will be launching a vaccine in six months for children, hopefully down to the age of three," Poonawalla said. He noted that already there are two companies in India who are licensed and their vaccines will be available soon. "I think yes, you should take and get your children vaccinated. There is no harm, these vaccines have been proven to be safe and efficacious and all of that. If you feel you want to get your children vaccinated by all means wait for government announcements on that and you go ahead with that. "Our vaccine Covovax will be launched for children in six months," Poonawalla said, adding that Covovax is under trial and has shown excellent data all the way down to the age group of three years. Further, Poonawalla said there was enough data to show that the vaccines will work and protect the children against the infectious disease. He pointed out that so far nothing can be said about the <keyword id="1609796" type="General" weightage="50" keywordseo="omicron" source="Orion">Omicron</keyword> variant as to how it would impact the children. "I don't know what will happen with Omicron but so far the children have not been affected very badly with this (COVID) virus. I think their body, cells and their lungs recover better," he said. SEE ALSO: <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/india/news/delhi-reports-four-new-cases-of-omicron-covid-19-variant-says-health-minister/articleshow/88274332.cms">Delhi reports four new cases of Omicron COVID-19 variant, says Health Minister</a> <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/international/news/china-reports-first-case-of-omicron-variant-in-the-port-city-of-tianjin-say-media-reports/articleshow/88273319.cms">China reports first case of Omicron variant in the port city of Tianjin, say media reports</a>

Serum Institute to roll out COVID-19 vaccine for children in six months, says CEO Adar Poonawalla

<keyword id="9626040" type="UNKNOWN" weightage="20" keywordseo="Covishield-vaccine">Covishield vaccine</keyword> offers protection from double mutant variant of novel coronavirus, shows a study by the <keyword id="395778" type="COMPANY" weightage="20" keywordseo="Centre-for-Cellular-and-Molecular-Biology">Centre for Cellular and Molecular Biology</keyword> (CCMB). CCMB Director Rakesh K. Mishra termed this as a very preliminary but encouraging result. "Early results using in vitro neutralisation assay show that both convalescent (prior infection) sera and <keyword id="9617748" type="COMPANY" weightage="20" keywordseo="covishield">Covishield</keyword> vaccinated sera offer protection against the B.1.617 variant, aka double mutant," he said in a tweet. The CCMB's finding came close on the heels of an announcement by the Indian Council of Medical Research (ICMR) that Covaxin neutralises multiple variants of SARS-CoV-2 and effectively works against the double mutant strain as well. Covaxin is India's first indigenous Covid vaccine developed by Bharat Biotech in collaboration with ICMR. Covishield has been developed by Oxford-Astrazeneca and is being produced by <keyword id="95879" type="COMPANY" weightage="20" keywordseo="Serum-Institute-of-India">Serum Institute of India</keyword>, <keyword id="2094" type="COMPANY" weightage="20" keywordseo="Pune">Pune</keyword>. Both Covaxin and Covishield are part of India's ongoing Covid vaccination programme. The 'double mutant' (B.1.617) is said to be responsible for the current surge in Covid-19 cases in <keyword id="13126" type="COMPANY" weightage="20" keywordseo="Maharashtra">Maharashtra</keyword> and other states in India. Scientists earlier feared that vaccines may not offer protection from 'double mutant' as it may escape the immune system. After the CCMB's latest announcement that Covishield too offers protection from 'double mutant', experts say this again underscore the need for people to get vaccinated. CCMB scientist Divya Tej Sowpati tweeted that the convalescent sera is from September 2020, hence most likely of an infection of a variant which is not B.1.617. He also pointed to misinformation and confusion about the circulating SARS-CoV-2 variants in India. Though B.1.617 is called 'double mutant', it is characterised by more than 15 mutations. "It got dubbed the 'double mutant' because of two <keyword id="16898" type="COMPANY" weightage="20" keywordseo="Spike">spike</keyword> mutations, L452R and E484Q, which were mutations of concern because of their immune escape properties, and possible high infectivity," wrote Sowpati, who is leading Covid-19 genomics at CCMB. According to him, B.1.618 is not the 'triple mutant'. "Triple Mutant: Again, WRONG name, because it has many more defining mutations. Dubbed 'triple' because in addition to the two mutations, it also has V382L in its Spike. This is a sub-lineage of B.1.617, found mainly in MH samples and also a bit in other states." He also clarified that B.1.618 which was first sampled in West Bengal in late October 2020, has nothing to do with B.1.617, except for a couple of shared variants that all SARS-CoV-2 strains have at this point such as D614G. According to him, the main concern with B.1.618 is that it is found in growing proportions in West Bengal and has the spike del145-146 as well as E484K, both of which are known immune escape mutations. The scientist said that the names of "double" and "triple" mutants are wrong and misleading and that they have no connection to the lineage seen in West Bengal. SEE ALSO: <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/science/environment/news/worsening-air-quality-amid-the-surging-covid-19-cases-could-add-to-the-pressure-on-indias-healthcare-system/articleshow/82213498.cms">Air pollution is back with a vengeance as industries play catch up — and that could further worsen the COVID-19 pandemic</a> <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/india/news/checkout-in-images-how-oxygen-is-being-transported-across-the-country-by-air-rail-and-road/slidelist/82212220.cms">By air, rail and road – how oxygen is being transported across India amidst a severe COVID-19 crisis</a> <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/science/health/news/aiims-icmr-new-guidelines-for-treatment-of-covid-19-patients-with-moderate-case/articleshow/82211333.cms">Simplified: AIIMS, ICMR new guidelines for treatment of patients with ‘moderate’ case of COVID-19</a>

Covishield vaccine also protects from 'double mutant' strain of COVID-19, says CCMB

<ul><li>Instead of allowing vaccine makers to charge customers different prices for the same vaccine, the government could offer subsidy for those who need it the most via direct cash transfer.</li><li>Allowing different prices offers an incentive to move the stock of vaccines to the buyers who pay more i.e. private hospitals.</li><li>That may leave a lot of poorer Indians waiting in queues for a long time to get their share of the jabs.</li><li>Even with direct cash transfer, there may be a need to cap prices and to declare hoarding as a criminal act to ensure that the kind of leakage seen in ration shops is not replicated in vaccines as well. </li><li>There are arguments against direct benefit transfer as well. </li></ul>The new prices for COVID-19 vaccine, Covishield, has triggered a debate in India. Some argue that the prices are too high for everyone to be able to afford, and some say that it should be free for all and the government should bear the cost. The government already has a lot of expenses piling up as it manages the pandemic, and hence, there are also those who see merit in arguing that those who can pay for the vaccine, must pay for it. However, there is a problem with letting private and for-profit companies charge different prices from different customers. These are the prices fixed by Serum Institute of India (SII) for the Covishield vaccine: <table style="border-width: initial; border-style: none; table-layout: fixed; width: 468pt;"></colgroup><tbody><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">If the vaccine is sold to… </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Price per dose </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Central government </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">₹150 </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">State government </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">₹400 </td></tr><tr><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">Private hospitals </td><td style="border-left:solid #000000 1pt;border-right:solid #000000 1pt;border-bottom:solid #000000 1pt;border-top:solid #000000 1pt;vertical-align:top;padding:5pt 5pt 5pt 5pt;overflow:hidden;overflow-wrap:break-word;">₹600 </td></tr></tbody></table> India is a developing country with millions of poor people with poor access to, and little money to spare for, healthcare. By allowing vaccine makers to choose the pricing based on who is buying the vaccine, the government may give the producer an incentive to direct more vaccines to the more expensive private hospitals, whereas a majority of the country still depends on state-run facilities. “Pricing should be uniform. Both the central and state governments should pay the same price for the vaccine. The government should also cap the price of the vaccine sold at private hospitals. Even the administrative charges should be capped. Otherwise a family of four may end up paying a lot for vaccination,” Doctor Sanjeev Bagai, Chairman and Managing Director of the New Delhi-based Nephron clinic told Business Insider. “Direct benefit transfer is also an option. And the cost of vaccination should be covered by all insurance companies,” Bagai added. <div type="image" title="Kolkata:Beneficiaries stands in a queue outside a health centre to receive a dos..." msid="82200586" hostid="261" caption="&amp;lt;p&amp;gt;Beneficiaries stands in a queue outside a health centre to receive a dose of Covid-19 vaccine, amid surge in coronavirus cases, in Kolkata.Photo/Swapan Mahapatra)(&amp;lt;/p&amp;gt;"></div> The case for direct reimbursement for the cost of vaccine One may argue that there are covenants in place to ensure that the company sends an agreed amount of supply to government facilities. However, decades of similar policy experiments have taught us that such agreements are inefficient and provide a fertile ground for corrupt practices. The failure of such mechanisms gave birth to the idea of Direct Benefit Transfer (DBT). It could be deployed here as well, given that patients coming in for vaccination are already being asked to submit their Aadhaar (unique identity number) details. Vaccine makers should charge the same price from all customers. Those who access it via government agencies, or any other filter as may be applicable, should be allowed to get the subsidy reimbursed to their bank account. This has been effectively used in transferring other subsidies like the ones for cooking gas and fertilisers. The government’s own estimate is that it has saved over ₹1.78 lakh crore ($25 billion) in subsidy leakage because of DBT. The argument against direct benefit transfer There are two arguments here against direct benefit transfer. One from R Ramakumar, Professor at Tata Institute of Social Sciences, who wants vaccines to be free for all as it is in countries like US, UK and China. The other argument is from Dr Arvind Virmani, an economist and the former Chief Economic Advisor to the government of India, who wants drug prices to be decontrolled totally and do a direct cash transfer on a larger scale and not limit it to vaccines alone. “Supply chain has to be developed. It can’t be done overnight. The data on production and sale of vaccines is transparently available from the producers, for the government, Astrazeneca and others to see. To introduce DBT now, it would mean taking out funding from other budgeted activities like infrastructure construction. Right now, vaccination is working smoothly. Don’t disrupt it,” he told Business Insider. Aside from the fact this may add a bureaucratic layer, Ramakumar’s contention is that by allowing state-run facilities to charge less, and private hospitals to charge more, there is an incentive of corruption in distribution. India already has decades of bad experience. from the public distribution system a.k.a the ration shops, where the subsidised stock is moved out to be sold at a higher price. A cap on prices, and a crackdown on hoarders by making it a criminal act, may be necessary to counter this, even with reimbursement of the vaccine cost via direct transfer to bank accounts. Virmani’s take is that there is a case to be made for both deregulating drug prices, as well as direct cash transfer for a variety of reasons, in India but that can’t be debated in the middle of a pandemic. “All drugs are controlled. We should be discussing decontrol of drugs. That’s not the problem right now. For the last 12 months, I have been saying you can create a direct cash transfer in 4 months. It should still be considered,” he added. SEE ALSO: <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/india/news/while-covid-19-is-making-millions-gasp-for-breath-in-india-state-administrations-are-trying-to-hoard-oxygen/articleshow/82199390.cms">While COVID-19 is making millions gasp for breath in India, state administrations are trying to hoard oxygen</a> <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/business/auto/news/covid-19-lockdowns-and-curfews-affecting-worlds-fourth-largest-automobile-market/articleshow/82195326.cms">There is a virtual lockdown in the world’s fourth largest automobile market</a> <a target="_blank" class="c-link c-message_attachment__title_link" href="https://www.businessinsider.in/business/startups/news/revolut-appoints-former-flipkart-exec-paroma-chatterjee-as-its-india-ceo/articleshow/82181199.cms">Revolut starts India operations, appoints former Lendingkart, Flipkart executive Paroma Chatterjee as CEO</a>

If the COVID-19 vaccine prices are too high for some, then why not use direct benefit transfer

Sri Lanka has temporarily halted its <keyword id="10199226" type="UNKNOWN" weightage="20" keywordseo="covid-19-vaccination-programme">COVID-19 vaccination programme</keyword> as there was a delay in securing <keyword id="11033857" type="UNKNOWN" weightage="20" keywordseo="more-astrazeneca-vaccines">more AstraZeneca vaccines</keyword> from the <keyword id="95879" type="COMPANY" weightage="20" keywordseo="Serum-Institute-of-India">Serum Institute of India</keyword>, a top health minister has said. Sri Lanka launched its inoculation programme late January when <keyword id="3658" type="LOCATION" weightage="20" keywordseo="India">India</keyword> gifted 500,000 doses of Oxford-AstraZeneca. Till Thursday 913,219 people out of the island nation's 21 million population had been <keyword id="178509" type="PERSON" weightage="20" keywordseo="vaccinated">vaccinated</keyword>. Vaccination programme has been halted from Wednesday night due to the need to use the available Oxford-AstraZeneca doses for the second jab of those already vaccinated, primary health care and COVID-19 prevention minister Dr Sudarshani Fernandopulle was quoted as saying by the Daily Mirror newspaper on Friday. She said the COVID-19 vaccination programme was temporarily suspended as there was a delay in securing more <keyword id="6409874" type="DOMAIN" weightage="20" keywordseo="astrazeneca">AstraZeneca</keyword> vaccines, the report added. The Serum Institute of India (SII) recently suspended exports of the AstraZeneca vaccine. The WHO has recommended that the second jab must be made available within 12 weeks of the first. The second dose was to be administered from April 19, the report said. After the free gift, Sri Lanka placed an order for more doses of the Indian vaccine. The Oxford-AstraZeneca vaccine, <keyword id="9617748" type="COMPANY" weightage="20" keywordseo="covishield">Covishield</keyword>, has been developed in collaboration with SII. The Pune-based vaccine major has entered into a collaboration with the University of Oxford and AstraZeneca to manufacture the vaccine. The Serum Institute had curtailed exports in the recent weeks. So, Fernandopulle said that Sri Lanka was not able to gain any assurances on the arrival of the next consignment from India in time. This week China donated 600,000 doses of Sinopharm vaccines. However neither the local health regulators or the WHO have approved its emergency use. Officials said the Chinese vaccine will be administered on the Chinese workers in the country. Sri Lanka is also to order 700,000 doses of the Russian Sputnik V vaccine. SEE ALSO: <a href="https://www.businessinsider.in/careers/news/paytm-money-set-to-hire-250-engineers-for-its-new-technology-centre-in-pune/articleshow/81813092.cms">Paytm Money set to hire 250 engineers for its new technology centre in Pune</a> <a href="https://www.businessinsider.in/finance/news/government-withdraws-interest-rate-cut-on-small-savings-schemes-in-a-bizarre-u-turn/articleshow/81813361.cms">Government withdraws interest rate cut on small savings schemes in a bizarre u-turn</a> <a href="https://www.businessinsider.in/stock-market/news/coursera-soars-23-in-trading-debut-following-4-3-billion-ipo/articleshow/81785440.cms">Coursera soars 23% in trading debut following $4.3 billion IPO</a> <a href="https://www.businessinsider.in/entertainment/news/indian-actor-rajinikanth-will-receive-the-51st-dadasaheb-phalke-award/articleshow/81818360.cms">Rajinikanth to receive the 51st Dadasaheb Phalke award</a> <a href="https://www.businessinsider.in/stock-market/news/wipro-share-price-jumps-over-1-after-117-million-acquisition-of-australian-cybersecurity-firm-ampion/articleshow/81817928.cms">Wipro's share price jumps over 1% after $117 million acquisition of Australian cybersecurity firm Ampion</a>

You Searched For "covishield vaccinated people" and got 6 results

After SII's Covishield, Bharat Biotech plans to put its COVID-19 vaccine for approval before expert panel

IANS

After UK and US, Italy also gives green pass to Covishield vaccine

IANS

Serum Institute to roll out COVID-19 vaccine for children in six months, says CEO Adar Poonawalla

PTI

Covishield vaccine also protects from 'double mutant' strain of COVID-19, says CCMB

IANS

If the COVID-19 vaccine prices are too high for some, then why not use direct benefit transfer

Sriram Iyer

Sri Lanka temporarily suspends COVID-19 jabs due to delay in securing vaccines from Serum Institute of India, says Health Minister

PTI

Popular Keywords

Buying Guides